Text Size

Parecoxib in Renal Colic

This study has been terminated.
(See Detailed Description)
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00139646
First received: August 29, 2005
Last updated: May 2, 2008
Last verified: May 2008
History of Changes
  Purpose

This is a phase III, multicenter, randomized, single blind study designed to evaluate the efficacy and tolerability of a single dose of parecoxib compared with diclofenac in the treatment of acute pain due to renal colic.


Condition Intervention Phase
Colic
 Drug: Parecoxib
Drug: Diclofenac
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: A Multicenter Single-Blind, Single Dose Efficacy and Safety Pilot Study Comparing Intramuscular Parecoxib and Diclofenac in Renal Colic

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Evaluation of efficacy through: time to onset of pain relief and time to remedication.

Secondary Outcome Measures:
  • Evaluation of efficacy through: Pain Intensity (VAS), Pain Relief (PR) and several measurements of analgesia that will be derived from VAS and PR Physician's Global Evaluation at 12 hours Patient's Global Evaluation at 12 hours

Estimated Enrollment: 50
Study Start Date: April 2002
Estimated Study Completion Date: April 2004
Detailed Description:

This study was prematurely discontinued May 3, 2004 due to slow recruitment. The decision to terminate the trial was not based on any safety concerns.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • diagnosis of renal colic;
  • baseline pain > 50 mm on VAS;

Exclusion Criteria:

  • evidence of neoplasm or any other severe disease of any organ, including any psychiatric illness;
  • active GI disease (e.g. Crohn's disease or ulcerative colitis) or any evidence of concomitant disease which may lead to early termination of the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00139646

Locations
Italy
Pfizer Investigational Site
Alessandria, Italy, 15100
Pfizer Investigational Site
Grosseto, Italy, 58100
Pfizer Investigational Site
Modena, Italy, 41100
Pfizer Investigational Site
Pavia, Italy, 27100
Pfizer Investigational Site
Siena, Italy, 53100
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00139646     History of Changes
Other Study ID Numbers: 124-IFL-0505-005, A3481007
Study First Received: August 29, 2005
Last Updated: May 2, 2008
Health Authority: Italy: Ministry of Health

Additional relevant MeSH terms:
Renal Colic
Colic
Abdominal Pain
Pain
Signs and Symptoms
Signs and Symptoms, Digestive
Diclofenac
Parecoxib
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
 Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents
Cyclooxygenase 2 Inhibitors

ClinicalTrials.gov processed this record on May 22, 2013